CMV chemotherapy for extensive urothelial carcinoma
- 1 December 1988
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 6 (3), 158-162
- https://doi.org/10.1007/bf00326793
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder LesionJournal of Urology, 1988
- Statistical and epidemiologic data on urologic cancerCancer, 1987
- Pre-Cystectomy Chemotherapy in Patients with Muscle Infiltrating Bladder CarcinomaScandinavian Journal of Urology and Nephrology, 1987
- The Fate of the Bladder in Patients with Metastatic Bladder Cancer Treated with Cisplatin, Methotrexate and Vinblastine: A Northern California Oncology Group StudyJournal of Urology, 1985
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Cyclophosphamide, Doxorubicin and Cisplatin Chemotherapy for Patients with Locally Advanced Urothelial Tumors with or without Nodal MetastasesJournal of Urology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Regional Lymph Node Metastasis From Bladder CancerJournal of Urology, 1981